# The Peptide Menu: What Has Human Trials and What Does Not

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-11-01

Canonical page: https://glpwatchdog.org/research/the-peptide-menu-what-has-human-trials

> In August 2026, 152 of the 560 sellers we tracked ran a peptide menu. We counted the human randomized trials behind each one. BPC-157: 226 papers, zero. The peptides with real evidence are the ones that became approved drugs.

## Key points

- BPC-157: 226 indexed papers, ZERO human randomized trials.
- The peptides with real evidence are the ones that became approved drugs, each for a specific condition.
- Tesamorelin's 26 trials are about HIV-associated lipodystrophy, and do not transfer.
- Counting papers is a crude instrument: good for spotting a zero, useless for ranking.

A large share of GLP-1 sellers now run a peptide menu alongside the injections. When we counted on August 19, 2026, **152 of the 560** in our register had a structured one. The menus look alike, and they mix things with decades of human trials behind them and things with none at all. This is that menu, sorted by what has been tested in people.

## The table

Every row was counted the same way on the same day: a plain PubMed search for the peptide, then the same search restricted to randomized controlled trials in humans. Seller counts come from the structured product menus in our own register.

*Peptides on seller menus, against the human trial record. PubMed counts pulled August 19, 2026. A count of papers is a crude measure and not a judgment of quality.*

| Peptide | Sellers offering it | Indexed papers | Human RCTs |
| --- | --- | --- | --- |
| Sermorelin | 113 | 331 | 19 |
| GHK-Cu (copper peptide) | 32 | 178 | 2 |
| PT-141 (bremelanotide) | 29 | 109 | 14 |
| **BPC-157** | 15 | 226 | **0** |
| Ipamorelin | 12 | 54 | 2 |
| Tesamorelin | 11 | 121 | 26 |
| CJC-1295 | 10 | 33 | 1 |
| MOTS-c | 5 | 250 | 4, none giving MOTS-c |
| [KPV](https://glpwatchdog.org/research/kpv-peptide-what-the-evidence-shows) | 3 | 53 | 0 |
| **Epitalon** | 1 | 132 | **0** |

> [NAD+](https://glpwatchdog.org/research/what-is-nad-plus) is left out of the table on purpose, because its row would mislead. It was the most-offered item of all in the same August 19 count (153 sellers), but the trials are of *oral precursors* while what is sold is an *injection*, and a 2026 systematic review found no outcomes trials of the injected form at all. It gets its own piece: [NAD+ injections and what the evidence shows](https://glpwatchdog.org/research/nad-injections-what-the-evidence-shows). The oral NMN and NR trials on aging are covered in [NAD+ and longevity](https://glpwatchdog.org/research/nad-and-longevity-what-the-trials-show).

## The pattern in that table

Read the last column against the first. The peptides carrying real human trial evidence are, almost without exception, the ones that became approved drugs. If the term is new to you, [what is peptide therapy?](https://glpwatchdog.org/research/what-is-peptide-therapy) sorts the menu into approved drugs, compounded peptides and research-use-only vials.

- **Tesamorelin** has 26 human randomized trials because it was developed into an approved product for a specific condition, excess abdominal fat in people with HIV-associated lipodystrophy.
- **Bremelanotide** has 14 for the same reason, in a completely different area: it was approved for hypoactive sexual desire disorder in premenopausal women.
- **Sermorelin** has 19, from its history as a growth-hormone agent rather than from anything to do with weight.
- **MOTS-c** shows the limit of this count. Its four records are exercise, heat and metformin studies that measured the body’s own MOTS-c. None gave MOTS-c to anyone.
- **BPC-157 and epitalon** have zero, across 226 and 132 indexed papers respectively. The research is real and mostly preclinical, in cells and animals. The few epitalon courses given to people are set out in [epitalon dosage and courses](https://glpwatchdog.org/research/epitalon-dosage-and-courses). [Thymosin alpha 1](https://glpwatchdog.org/research/thymosin-alpha-1-evidence) is the instructive exception: licensed abroad, mainly for hepatitis B, it has human trials, though not for the uses it is sold for here.

> Evidence attaches to a drug for an indication, not to a molecule in general.

That sentence is the one worth taking away, because it is where the marketing goes wrong even when the citations are genuine. Tesamorelin’s 26 trials are excellent evidence for what tesamorelin does in HIV-associated lipodystrophy. They are not evidence about a person without HIV buying it for belly fat, and the trials cannot be borrowed across. We look at that specific gap in [tesamorelin for weight loss](https://glpwatchdog.org/research/tesamorelin-for-weight-loss).

## What a zero means, and what it does not

Zero human randomized trials does not mean a substance was tested and failed. It means the test has not been run, which is where [LL-37](https://glpwatchdog.org/research/ll-37-a-peptide-with-no-human-trials) stands despite thousands of papers. [AOD-9604](https://glpwatchdog.org/peptides/aod-9604) is the weight-loss peptide that was tested in people and failed, as [peptides for weight loss](https://glpwatchdog.org/research/peptides-for-weight-loss) sets out. The same is true of non-peptides sold on these menus, such as [5-amino-1MQ](https://glpwatchdog.org/research/5-amino-1mq-what-the-evidence-shows), which has mouse data and no published human study. [Tesofensine](https://glpwatchdog.org/research/tesofensine-what-the-evidence-shows) is the opposite case: real human trials, and still no approval. Those are different situations, and we keep them apart. The register has no interest in dismissing something that might turn out to work.

But it does settle one thing. Where there are no human trials, nobody knows the dose, the duration or [what happens over years](https://glpwatchdog.org/research/are-peptides-safe), and that includes the clinic writing the prescription. For BPC-157, the few doses ever given to people are set out in [BPC-157 dosage in the studies](https://glpwatchdog.org/research/bpc-157-dosage-in-the-studies). Any confident claim made to you about benefit is coming from somewhere other than a trial in people. What a lab panel can and cannot show about these products is covered in [peptide blood work](https://glpwatchdog.org/research/peptide-blood-work-and-monitoring). For BPC-157 specifically there is also a regulatory dimension, covered in [what the FDA actually said about BPC-157](https://glpwatchdog.org/research/bpc-157-what-fda-actually-said), and a short human safety record, covered in [BPC-157 side effects](https://glpwatchdog.org/research/bpc-157-side-effects).

> **The counts above are a crude instrument and should be treated as one.** A count of indexed papers says nothing about whether the trials were good, how large they were, or whether they measured anything a patient would notice. It is a rough map of where human evidence exists at all. That makes it useful for spotting a zero and useless for ranking a 19 against a 26.

## Questions worth asking about anything on the menu

1. **Which condition was it tested in, and am I that person?** This single question disposes of most peptide marketing.
2. **Was it tested in people, or in cells and animals?** Preclinical work is real science and it is not a reason to buy something today.
3. **What dose, for how long, and from what?** Where there are no human trials, these numbers came from somewhere other than evidence.
4. **Can it lawfully be compounded at all?** Some cannot (see [what cannot legally be compounded](https://glpwatchdog.org/research/what-cannot-legally-be-compounded)).
5. **Who made it, and will they tell me?** Covered in [what makes a telehealth prescription legitimate](https://glpwatchdog.org/research/what-makes-a-telehealth-glp1-prescription-legitimate).

## Frequently asked questions

### Does BPC-157 have any human trials?

Not randomized ones. A search on August 19, 2026 returned 226 indexed papers and zero human randomized controlled trials. The research that exists is largely preclinical, in cells and animals. That is an absence of testing rather than a failed test, but it means the dose, duration and long-term picture are unknown to everyone, including whoever is selling it.

### Which peptides on these menus have evidence?

Overwhelmingly the ones that became approved drugs for a specific condition: tesamorelin (26 human randomized trials), bremelanotide or PT-141 (14), and sermorelin (19). Among those sold purely as wellness products, BPC-157, epitalon and KPV sit at zero and CJC-1295 at one. MOTS-c shows four, but those studies measured the body's own MOTS-c; none gave it as a treatment.

### If tesamorelin has 26 trials, is it proven for belly fat?

It is proven for the condition it was studied and approved in: excess abdominal fat in people with HIV-associated lipodystrophy. Evidence attaches to a drug for an indication, not to a molecule in general, so those trials do not carry across to someone without HIV buying it for general fat loss.

### How reliable is counting papers like this?

As a rough map only. It shows where human evidence exists at all, which is enough to spot a zero, but it says nothing about trial quality, size, or whether the endpoints mattered. It is also sensitive to how the search is built. An earlier version of this count using a title-and-abstract restriction reported sermorelin at zero when the correct figure is 19, because it missed records indexed under a subject heading.

### Why do GLP-1 sellers offer peptides at all?

Because the same visit and the same shipping already exist, so an added product is close to pure margin. When we counted on August 19, 2026, 152 of the 560 sellers in our register ran a structured peptide menu alongside their GLP-1 offering.

## References

1. National Library of Medicine. PubMed — record counts by peptide and by publication type, retrieved August 19, 2026; every row queried identically (plain term, then the same term restricted to randomized controlled trial[pt] AND humans[mh]). PubMed. 2026. https://pubmed.ncbi.nlm.nih.gov/

---

Cite as: GLP Watchdog, Nora Bissett, "The Peptide Menu: What Has Human Trials and What Does Not", published 2026-08-19, updated 2026-11-01. https://glpwatchdog.org/research/the-peptide-menu-what-has-human-trials

Canonical HTML page: https://glpwatchdog.org/research/the-peptide-menu-what-has-human-trials

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
